CTRI/2023/03/050799尚未招募Unknown
Evaluation of the Effects of Dapaglifozin (sglt-2 inhibitor) on Hepatic Steatosis and fibrosis using Anthropometric, Biochemical and Radiological indices in patients with type 2 Diabetes Mellitus and Non Alcoholic fatty liver disease
Department of medicine Jawaharlal Nehru medical college and hospital AMU Aligarh0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- Unknown
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Diagnosed type 2 DM patients on standard treatment for diabetes whether be it Insulin or oral hypoglycemic agents except all SGLT2 Inhibitors
- •2. Patients diagnosed with NAFLD made on the basis of history of low daily alcohol intake ( < 30 g for men and < 20 g for women), liver biochemistry, presence of fatty liver on ultrasonography and transient elastography.
- •3. Patients giving informed consent
排除标准
- •1. Patients with other causes of chronic liver disease like chronic viral hepatitis, autoimmune hepatitis, excessive alcoholic consumption, drug-induced liver injury, biliary tract disease, decompensated liver cirrhosis, hepatocellular carcinoma, history of diabetic ketoacidosis
- •2. Patients with co-administration of medications that may affect liver function tests (such as NSAIDS, Vitamin E, pioglitazone, saroglitazar, statin, and TZDs)
- •3. Presence of severe comorbidities such as CAD, CHF, CKD, COPD, pyelonephritis and chronic UTI
研究者
相似试验
进行中（未招募）
不适用
Impact of treatment with Dapagliflozin in type 1 diabetic patientsType 1 diabetesEUCTR2015-002963-40-ESDra Cristina Avendaño Sola
已完成
1 期
Dapagliflozin Effects on HypoglycemiaType1 Diabetes MellitusNCT03704818University of California, San Diego22
进行中（未招募）
1 期
Study to evaluate if dapagliflozin treatment is effective in patients with heart failure by reducing the number of hospitalizations and urgent visits due to heart failure, and by reducing the risk of death.Chronic Heart Failure (HF) with Reduced Ejection FractionEUCTR2016-003897-41-PLAstraZeneca AB4,500
进行中（未招募）
1 期
Study to evaluate if dapagliflozin treatment is effective in patients with heart failure by reducing the number of hospitalizations and urgent visits due to heart failure, and by reducing the risk of death.Chronic Heart Failure (HF) with Reduced Ejection FractionEUCTR2016-003897-41-BGAstraZeneca AB4,500
进行中（未招募）
1 期
Study to evaluate if dapagliflozin treatment is effective in patients with heart failure by reducing the number of hospitalizations and urgent visits due to heart failure, and by reducing the risk of death.EUCTR2016-003897-41-SEAstraZeneca AB4,500